MAPT and Alzheimer disease: Multi-omic AD cohorts (combining PET imaging of amyloid/tau with transcriptomic profiling) could reveal subgroups with heightened neuroinflammation or synaptic loss, markers that GLP-1RAs might reverse [148,150].